Cartalax Dosage Calculator
Calculate Cartalax peptide bioregulator dosing, reconstitution volume, and syringe draw units. Includes subcutaneous injection and oral capsule protocols. This calculator performs math conversions only — Cartalax is not FDA-approved. It does not recommend doses for unsupervised use.
Cartalax Research Protocol
Enter your protocol phase and parameters to see common Cartalax research dosing patterns. No FDA-approved dose exists — these are math conversions from Khavinson peptide bioregulator research, not medical recommendations.
Cartalax Common Research Ranges
| Phase | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Standard injection | 100–300 mcg/day | SubQ | 1x daily | 10–20 days |
| Oral capsule | 1–2 capsules/day | Oral | 1–2x daily | 20–30 days |
| Loading injection | 200–500 mcg/day | SubQ | 1x daily | 5–10 days |
| Lower-dose exploratory | 50–100 mcg/day | SubQ | 1x daily | 10–15 days |
| Maintenance cycle | 100–200 mcg/day | SubQ or Oral | 2–3x/week | 30 days |
Key Properties
- Family: Khavinson peptide bioregulator (cartilage-targeting)
- Mechanism: Tissue-specific peptide bioregulator targeting chondrocytes and connective tissue
- Routes: Subcutaneous injection or oral capsules
- Legal status: Not FDA-approved — research only
- Cycle break: 1–3 months off between research cycles
- Cumulative effect: Discussed in terms of cumulative benefit over a full course, not immediate effects
- This calculator performs math conversions only — it does not verify product quality, safety, or medical appropriateness
Reconstitution Calculator
Calculate how much bacteriostatic water to add and how many units to draw on your syringe for your Cartalax subcutaneous dose. For oral capsules, use concentration reference only.
Enter values and click Calculate
How Reconstitution Works
- Determine concentration: Divide peptide amount by water volume (e.g., 5 mg ÷ 1 mL = 5 mg/mL = 5000 mcg/mL)
- Calculate draw volume: Divide your dose by concentration (e.g., 200 mcg ÷ 5000 mcg/mL = 0.04 mL)
- Convert to syringe units: Multiply mL by 100 for U-100 syringes (0.04 mL = 4U) — for SubQ route only
- For oral capsules: Use concentration to verify capsule content matches your target dose
Example Calculation (SubQ)
Vial: 5 mg Cartalax
Water: 1 mL bacteriostatic
Dose: 200 mcg
Syringe: 100U (1 mL)
Concentration: 5 mg ÷ 1 mL = 5000 mcg/mL
Draw volume: 200 mcg ÷ 5000 mcg/mL = 0.04 mL = 4U on a U-100 syringe
Oral Capsule Note
For oral capsule use, the concentration determines how much active peptide each capsule contains. Oral bioavailability is lower than injection — typical oral doses are 1–2 capsules daily for 20–30 days. Always verify the labeled content per capsule and follow the manufacturer's instructions.
Cartalax Dosage Calculator
If you are searching for a Cartalax dosage calculator, you may be trying to organize a peptide bioregulator protocol into a clear plan. This calculator helps with the math — concentration, draw volume, syringe units, and phase-based scheduling for both subcutaneous injection and oral capsule routes. It does not provide medical recommendations. Cartalax is not FDA-approved and no safe therapeutic dose has been established in Western clinical trials.
What is Cartalax?
Cartalax is a peptide bioregulator in the Khavinson family, developed in Russian medical research for tissue-specific regeneration. Unlike broader peptides that affect multiple systems, Cartalax is designed to target cartilage cells (chondrocytes) and connective tissue structures. The compound is available in two forms — injectable (subcutaneous) and oral (capsules) — reflecting the Khavinson design philosophy of providing both intensive and maintenance options. The injectable route provides higher bioavailability for loading protocols, while oral capsules support longer maintenance cycles.
Subcutaneous injection vs oral capsule dosing
The subcutaneous injection route is the primary research route for intensive Cartalax protocols. Typical injection doses range from 100 to 500 mcg per day, administered once daily for 5 to 20 days depending on the phase. Oral capsules provide a lower-bioavailability alternative suitable for maintenance cycles, typically 1 to 2 capsules daily for 20 to 30 days. The calculator above reflects both routes with appropriate dose ranges for each phase.
Cumulative effect and dosing implications
Peptide bioregulators in the Khavinson family are discussed in terms of cumulative benefit over a full course of administration, not immediate effects. This means a 10 to 30 day course is typically needed before any potential benefit may be observed. Discontinuing early may not allow the cumulative mechanism to produce visible results. The calculator accounts for this by offering duration options that match standard research protocols, along with cycle breaks of 1 to 3 months between courses.
Safety and limitations
Cartalax is not FDA-approved for any therapeutic use. The compound has not undergone FDA review for safety, effectiveness, or quality. Most evidence comes from Russian research on the Khavinson peptide family, and direct clinical evidence in Western medical literature is limited. Reported side effects include injection site reactions (redness, pain, irritation) with subcutaneous use and mild nausea. Long-term effects have not been systematically studied. Do not combine with other joint-support peptides without medical supervision. Discuss any protocol with a licensed healthcare provider.
For a full guide on Cartalax protocols, dosing charts, safety considerations, and route differences, read our Cartalax Peptide Dosing Guide →